J&J Increases Alza Ante By $5 Bil. Over Abbott: Concerta Has J&J Upbeat
Executive Summary
Johnson & Johnson is offering about 67% ($5 bil.) more than Abbott did in 1999 to bring Alza's $700 mil. annual sales product line and its extended-release product development skills into the J&J family.
You may also be interested in...
J&J Acquires Crystalline Technology Through $230 Mil. TransForm Buy
Johnson & Johnson will have access to all of TransForm Pharmaceuticals' proprietary crystalline formulation technology through its proposed $230 mil. acquisition of the privately held company
J&J Patches Together Strong Sales Growth With Ortho EVRA, Duragesic
J&J will step up promotion of Ortho EVRA in the fourth quarter, marking the end of supply constraints for the contraceptive patch
J&J Patches Together Strong Sales Growth With Ortho EVRA, Duragesic
J&J will step up promotion of Ortho EVRA in the fourth quarter, marking the end of supply constraints for the contraceptive patch